Cutaneous Squamous Cell

Adjuvant

Complete macroscopic resection of all known cSCC disease with or without microscopic positive margins. Confirmed LA cSCC with a high-risk features.

SKIN0046
Phase III Pembrolizumab vs Placebo as in HighRisk Locally Advanced Cutaneous Squamous Cell Carcinoma

PI: Chang Pending

History of recurrent resectable cSCC that was surgically removed within 3 years.

SKIN0043
Phase I Pre-Operative Cemiplimab (REGN2810) in Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

PI: Chang Pending

Locally advanced cSCC only Q3 systemic Previously treated with Platinum or Cetuximab continuing regimen

SKIN0039
Phase II Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

PI: Chang Mark Sharp & Dohme

KEY

Pending
Open for Enrollment
Observational Study
Linked
Trial Posting
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu